Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
4203 participants
INTERVENTIONAL
2006-09-30
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Age-Related Eye Disease Study (AREDS)
NCT00000145
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
NCT03367767
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
NCT00121589
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
NCT01915238
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
NCT03946085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Multiple ancillary studies were conducted using the parent study (AREDS2) data to explore:
1. Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin, zinc, and beta-carotene on cognitive function
1. Outcome is measured with a battery of tests administered over the telephone at baseline, and at years 2 and 4 of the study.
2. Primary outcome is the change in the composite score for the results of the cognitive function testing from baseline over time.
2. Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on cardiovascular disease
a. Primary measure of cardiovascular morbidity and mortality
3. Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on the peripheral retina
a. Primary outcome is the development of peripheral drusen, geographic atrophy, reticular pigmentary changes, and pseudoreticular drusen.
4. Association of genotype polymorphisms with age-related macular degeneration and cataract
a. Whole genome sequencing will be completed. Evaluation of association genetic associations with disease will be conducted using AREDS controls.
5. Association of genotype polymorphisms with progression of age-related macular degeneration
a. Whole genome sequencing is conducted. Progression from early to late and severe stages of AMD will be examined with the genotype data to evaluate the risks of progression associated with the genotype polymorphisms.
6. Association of genotype polymorphisms with dietary intake a. Whole genome sequencing is conducted. Progression from early to late and severe stages of AMD will be examined regarding potential interaction of the dietary intake with the genotype data to evaluate the risks of progression.
7. Association of genotype polymorphisms with AREDS2 supplements a. Interaction of genetic polymorphisms with AREDS2 supplements for progression to late AMD will be evaluated using the data from the whole genome sequencing project.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lutein/Zeaxanthin
lutein (10mg)/zeaxanthin (2 mg)
Lutein/zeaxanthin
10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
DHA/EPA
DHA (350 mg)/EPA (650 mg)
DHA/EPA
Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Lutein/Zeaxanthin + DHA/EPA
lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
Lutein/zeaxanthin and DHA/EPA
10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Placebo/Control
Considered control because all participants received the AREDS formulation
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lutein/zeaxanthin
10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
DHA/EPA
Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Lutein/zeaxanthin and DHA/EPA
10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Macular status ranges from large drusen in both eyes or large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye
Exclusion Criteria
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Office of Dietary Supplements (ODS)
NIH
National Center for Complementary and Integrative Health (NCCIH)
NIH
National Eye Institute (NEI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emily Y Chew, MD
Role: STUDY_CHAIR
National Eye Institute, National Institutes of Health
John Paul SanGiovanni, Sc.D.
Role: STUDY_DIRECTOR
National Eye Institute, National Institutes of Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Jones Eye Institute - UAMS
Little Rock, Arkansas, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Shiley Eye Center - UCSD
La Jolla, California, United States
Loma Linda University
Loma Linda, California, United States
Doheny Eye Institute
Los Angeles, California, United States
Jules Stein Eye Institute
Los Angeles, California, United States
VA Northern California Health Care System
Martinez, California, United States
Southern California Desert Retina Consultants, MC
Palm Springs, California, United States
University of California, Davis
Sacramento, California, United States
West Coast Retina Medical Group, Inc
San Francisco, California, United States
Pacific Eye Associates
San Francisco, California, United States
Colorado Retina Associates
Denver, Colorado, United States
Eldorado Retina Associates, PC
Louisville, Colorado, United States
Yale University Eye Center
New Haven, Connecticut, United States
Retina Group of Florida
Fort Lauderdale, Florida, United States
University of Florida
Jacksonville, Florida, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Sarasota Retina Institute
Sarasota, Florida, United States
Center for Retina and Macular Disease
Winter Haven, Florida, United States
Emory University Eye Center
Atlanta, Georgia, United States
Georgia Retina, PC
Decatur, Georgia, United States
Northwestern University
Chicago, Illinois, United States
The University of Illinois
Chicago, Illinois, United States
NorthShore University HealthSystems
Glenview, Illinois, United States
Ingalls Memorial Hospital
Harvey, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
Retina Associates of Kentucky
Lexington, Kentucky, United States
Paducah Retinal Center
Paducah, Kentucky, United States
Elman Retina Group
Baltimore, Maryland, United States
Wilmer Eye Institute, Johns Hopkins Hospital
Baltimore, Maryland, United States
National Eye Institute
Bethesda, Maryland, United States
The Retina Group of Washington
Chevy Chase, Maryland, United States
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Kresge Eye Institute
Detroit, Michigan, United States
Henry Ford Health System - Eye Care Services
Detroit, Michigan, United States
Vision Research Foundation
Grand Rapids, Michigan, United States
Vision Research Foundation
Royal Oak, Michigan, United States
Vision Research Foundation
Traverse City, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
University Health Care - Mason Eye Institute
Columbia, Missouri, United States
Eye Foundation of Kansas City
Kansas City, Missouri, United States
Mid-America Retina Consultants, PA
Kansas City, Missouri, United States
The Retina Institute
St Louis, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Delaware Valley Retina Associates
Lawrenceville, New Jersey, United States
UMDNJ
Newark, New Jersey, United States
Ophthalmic Consultants of Long Island
Lynbrook, New York, United States
New York Eye and Ear Infirmary
New York, New York, United States
Manhattan Eye, Ear and Throat Hospital
New York, New York, United States
University of Rochester Eye Institute
Rochester, New York, United States
Retina Consultants, PLLC
Slingerlands, New York, United States
The Research Foundation of SUNY/Stony Brook
Stony Brook, New York, United States
Western Carolina Retinal Associates
Asheville, North Carolina, United States
UNC Department of Ophthalmology
Chapel Hill, North Carolina, United States
Charlotte Eye Ear Nose and Throat Associates
Charlotte, North Carolina, United States
Duke University
Durham, North Carolina, United States
Wake Forest University Eye Center
Winston-Salem, North Carolina, United States
Case Western Reserve University
Cleveland, Ohio, United States
Retina Associates of Cleveland
Cleveland, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Retina Associates of Cleveland
Middleburg Heights, Ohio, United States
Retina Associates of Cleveland
Youngstown, Ohio, United States
Dean McGee Eye Institute
Oklahoma City, Oklahoma, United States
Devers Eye Institute
Portland, Oregon, United States
Retina Northwest, PC
Portland, Oregon, United States
Pennsylvania Retina Specialists, PC
Camp Hill, Pennsylvania, United States
Penn State M.S. Hershey Medical Center
Hershey, Pennsylvania, United States
Scheie Eye Institute
Philadelphia, Pennsylvania, United States
Wills Eye Hospital/Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Retina Vitreous Consultants
Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Palmetto Retina Center
Columbia, South Carolina, United States
Carolina Retina Center
Columbia, South Carolina, United States
Southeastern Retina Associates, PC
Knoxville, Tennessee, United States
University of Tennessee
Memphis, Tennessee, United States
Vanderbilt Eye Institute
Nashville, Tennessee, United States
Texas Retina Associates
Arlington, Texas, United States
Texas Retina Associates
Dallas, Texas, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Retina Consultants of Houston
Houston, Texas, United States
Texas Retina Associates
Lubbock, Texas, United States
Scott and White Memorial Hospital
Temple, Texas, United States
John Moran Eye Center
Salt Lake City, Utah, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
The Retina Group of Washington
Fairfax, Virginia, United States
Retina Center Northwest
Silverdale, Washington, United States
University of Wisconsin
Madison, Wisconsin, United States
The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5.
Bhandari S, Vitale S, Agron E, Clemons TE, Chew EY; Age-Related Eye Disease Study 2 Research Group. Cataract Surgery and the Risk of Developing Late Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 Report Number 27. Ophthalmology. 2022 Apr;129(4):414-420. doi: 10.1016/j.ophtha.2021.11.014. Epub 2021 Nov 16.
Keenan TD, Agron E, Mares JA, Clemons TE, van Asten F, Swaroop A, Chew EY; AREDS and AREDS2 Research Groups. Adherence to a Mediterranean diet and cognitive function in the Age-Related Eye Disease Studies 1 & 2. Alzheimers Dement. 2020 Jun;16(6):831-842. doi: 10.1002/alz.12077. Epub 2020 Apr 13.
Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F, Bernstein PS; Age-Related Eye Disease Study 2 (AREDS2) Research Group. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA. 2015 Aug 25;314(8):791-801. doi: 10.1001/jama.2015.9677.
Writing Group for the AREDS2 Research Group; Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, Hsia J, Robinson J, Clemons TE, Fine LJ, Chew EY. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med. 2014 May;174(5):763-71. doi: 10.1001/jamainternmed.2014.328.
Age-Related Eye Disease Study 2 (AREDS2) Research Group; Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3rd, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agron E, Toth CA, Bernstein PS, Sperduto RD. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014 Feb;132(2):142-9. doi: 10.1001/jamaophthalmol.2013.7376.
Domalpally A, Danis RP, Chew EY, Clemons TE, Reed S, Sangiovanni JP, Ferris FL 3rd; Age-Related Eye Disease Study 2 Research Group. Evaluation of optimized digital fundus reflex photographs for lens opacities in the age-related eye disease study 2: AREDS2 report 7. Invest Ophthalmol Vis Sci. 2013 Sep 5;54(9):5989-94. doi: 10.1167/iovs.13-12301.
Toy BC, Krishnadev N, Indaram M, Cunningham D, Cukras CA, Chew EY, Wong WT. Drusen regression is associated with local changes in fundus autofluorescence in intermediate age-related macular degeneration. Am J Ophthalmol. 2013 Sep;156(3):532-542.e1. doi: 10.1016/j.ajo.2013.04.031. Epub 2013 Jul 3.
Age-Related Eye Disease Study 2 (AREDS2) Research Group; Chew EY, SanGiovanni JP, Ferris FL, Wong WT, Agron E, Clemons TE, Sperduto R, Danis R, Chandra SR, Blodi BA, Domalpally A, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Friberg TR, Rosenfeld PJ, Toth CA, Bernstein P. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol. 2013 Jul;131(7):843-50. doi: 10.1001/jamaophthalmol.2013.4412.
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15;309(19):2005-15. doi: 10.1001/jama.2013.4997.
Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). Invest Ophthalmol Vis Sci. 2013 Jul 8;54(7):4548-54. doi: 10.1167/iovs.13-11804.
Bernstein PS, Ahmed F, Liu A, Allman S, Sheng X, Sharifzadeh M, Ermakov I, Gellermann W. Macular pigment imaging in AREDS2 participants: an ancillary study of AREDS2 subjects enrolled at the Moran Eye Center. Invest Ophthalmol Vis Sci. 2012 Sep 14;53(10):6178-86. doi: 10.1167/iovs.12-10275.
Hubbard LD, Danis RP, Neider MW, Thayer DW, Wabers HD, White JK, Pugliese AJ, Pugliese MF; Age-Related Eye Disease 2 Research Group. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3269-82. doi: 10.1167/iovs.07-1267. Epub 2008 Apr 17.
Related Links
Access external resources that provide additional context or updates about the study.
NEI Website: Age-Related Eye Disease Study 2
AREDS2 Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N01-EY-5-0007
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
HHS-N-260-2005-00007-C
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CC-070025
Identifier Type: OTHER
Identifier Source: secondary_id
07-EI-0025
Identifier Type: OTHER
Identifier Source: secondary_id
NEI-120
Identifier Type: -
Identifier Source: org_study_id
NCT00409513
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.